2. CIRRHOSIS
WHO Definition: A diffuse process characterised
by liver necrosis and fibrosis and conversion of
normal liver architecture into structurally
abnormal nodules that lack normal lobular
organisation.
4. flow leads to portal hypertension and the formation of vascular shunts
between portal and systemic veins.
When the pressure gradient between the portal and hepatic veins exceeds
10 to 12 mm Hg, portal hypertension is severe, and complications such as
ascites, esophageal variceal bleeding, encephalopathy, and hepatorenal
syndrome occur.
Cirrhosis is the end product of chronic parenchymal
inflammation and necrosis, which results in fibrosis and
disruption of hepatic architecture. Resistance to blood
5.
6. Cardiovascular Complications
Hyperdynamic circulation—characterized by a high cardiac output, low
arterial blood pressure, and low systemic vascular resistance—is the
hallmark of end-stage liver disease.
Patients appear well perfused despite systolic arterial pressures less
than 100 mm Hg.
Pulmonary arterial pressures may be mildly elevated because of
increased flow; however, the pulmonary vascular resistance (PVR) is
usually within the normal range.
These patients have an elevated intravascular volume that is
sequestered into a dilated splanchnic vascular bed.
The effective circulating volume is typically reduced.
7.
8.
9.
10. Pulmonary Complications:
50% to 70% of patients with chronic liver disease complain of shortness
of breath.
The differential diagnosis includes ventilation-perfusion abnormalities
associated with underlying obstructive airways disease, fluid
retention, pleural effusion, and decreased lung capacities secondary
to large volume ascites.
Alpha-1 antitrypsin deficiency has both lung and liver manifestations,
as does cystic fibrosis.
In addition, there are two types of vascular abnormalities unique to the
setting of portal hypertension, and they have significant morbidity and
mortality.
11. These abnormalities, hepatopulmonary syndrome (HPS) and
portopulmonary hypertension (PPHTN).
The diagnostic criteria for HPS include portal hypertension, PaO2 less than
80 mm Hg on room air (or alveolar-arterial oxygen gradient greater than
15 mm Hg), and evidence of intrapulmonary vascular dilation (IPVD).
12. The natural history of HPS is usually one
of progressive hypoxemia.
13. capillary blood. As a result, the central stream of poorly
oxygenated blood is functionally shunted.
This lesion is typically correctable with the administration of
oxygen.
Because IPVDs predominate in the bases of the lungs,
standing worsens hypoxemia compared with the supine
position - ORTHODEOXIA
This IPVD together with the usually hyper dynamic
circulation of the cirrhotic patient, allows insufficient
time for oxygen diffusion through the entire stream of
14. PPHTN is defined as pulmonary hypertension in the presence of portal
hypertension in a patient without other predisposing factors. The European
Respiratory Society Task Force on Hepatopulmonary Disease diagnostic
criteria are:
(1)clinical evidence of portal hypertension with or without hepatic disease;
(2)mean pulmonary artery pressure of 25 mm Hg at rest or 30 mm Hg
during exercise;
(1)mean pulmonary artery occlusion pressure less than 15 mm Hg or
transpulmonary gradient (mean PA pressure minus wedge pressure)
greater than 12 mm Hg; and
(4)PVR greater than 240 dyn·s·cm–5 or 3 Wood Units.
15. Mild PPHTN :
Moderate PPHTN :
Severe PPHTN :
mean PA pressure less than 35 mm Hg
35 to 50 mm Hg
greater than 50 mm Hg
16. The occurrence of PPHTN is unrelated to the severity of the underlying
liver disease.
Similar to HPS, the symptoms of PPHTN are nonspecific, commonly
consisting of dyspnea, generalized weakness, and decreased exercise
tolerance.
The single best screening study for PPHTN is two dimensional
transthoracic echocardiography, which estimates right ventricular
systolic pressure using the velocity of the tricuspid regurgitant jet.
In the absence of pulmonary valvular stenosis, right ventricular
systolic pressure is a good estimate of pulmonary arterial systolic
pressure.
17.
18. The requirement for calculation of the PVR is a reflection of the fact that
many patients with cirrhosis have mildly elevated mean pulmonary
artery pressure based simply on an elevated cardiac output.
(epoprostenol),phosphodiesterase inhibitors (sildenafil), and
endothelin antagonists
(bosentan).
Calcium channel blockers, often used in noncirrhotic patients with
pulmonary hypertension, are contraindicated in patients with cirrhosis
because the associated mesenteric vasodilation worsens portal
hypertension.
Patients who respond to treatment sufficiently to reduce their mean PA
pressure below 35 mm Hg and PVR below 400 dyn·s·cm–5 should be
considered suitable transplant candidates.
20. Hepatorenal Syndrome
•Hepatorenal syndrome is the development of renal failure in patients with
advanced chronic liver disease and occasionally fulminant hepatitis, who have
portal hypertension and ascites.
•The hallmark of HRS is renal vasoconstriction.
21.
22.
23.
24.
25. Hepatorenal syndrome (HRS) is a prerenal abnormality caused by
circulatory derangements of advanced cirrhosis.
It is considered a functional disorder, based on successful
transplantation of kidneys from patients with HRS.
Renal function is an important risk factor for mortality, a fact that is
emphasized by its presence as one of only three variables used in
calculating the Model for End-Stage Liver Disease (MELD) score.
In addition to HRS, patients with cirrhosis are also at risk for other
causes of renal dysfunction, such as parenchymal renal disease,
sepsis, nephrotoxicity, and hypovolemia.
HRS is a diagnosis of exclusion, and other treatable causes must be
ruled out
26. Although renal vasoconstriction is the proximate cause of HRS, therapy
aimed at directly increasing renal perfusion by the use of
prostaglandins, dopamine agonists, or endothelin antagonists has not
proven to be successful.
Vasoconstrictor therapy targeting the underlying splanchnic
vasodilation is more effective.
These therapies include arginine vasopressin, somatostatin, and α-
agonists such as norepinephrine and midodrine, combined with
volume expansion
30. Signs of HE: The first signs of hepatic encephalopathy can be subtle and
nonspecific—change in sleep patterns, change in personality, irritability,
and mental dullness. Later confusion, disorientation, stupor, and
eventually coma supervene.
HE is exceptional in that, it has a fluctuating symptomatology which
ranges from mild neurological impairment that may progress to deep
coma fast and resolve again in hours.
31. CNS examination: Trail-making test, where patient is asked to connect a
series of 25 numbered circles as rapidly as possible using a pencil.
A normal person can finish the test in 15–30 s; it is considerably
delayed in patients with early hepatic encephalopathy.
32. Micrographia may be an early sign.
Patient may be asked to draw abstract objects or a fresh
signature may be compared to previous signatures.
More sophisticated testing includes electroencephalography and
visual evoked potentials which can detect mild forms of
encephalopathy, but these are rarely clinically useful.
34. Because cirrhotic patients are exquisitely sensitive to sedative
medications and have impaired hepatic (and often renal)
metabolism, a careful search for possible drug- related
encephalopathy should be undertaken.
35. Factors precipitating HE are given below:
Increased nitrogen load
–– Gastrointestinal bleeding
–– Excess dietary protein
–– Azotemia
–– Constipation
Disturbances of internal milieu
–– Hypovolemia
–– Metabolic alkalosis/acidosis
–– Hypoxia
–– Hyponatremia, hypokalemia
Drugs
–– Narcotics, tranquilizers, sedatives
Others
37. Therapy to reduce ammonia levels consists of the non
absorbable disaccharide lactulose and non absorbable
antibiotics such as neomycin, metronidazole, and rifaximin.
Nonabsorbable antibiotics appear to be equally effective to
nonabsorbable disaccharides, but concerns about toxicity
associated with long-term administration limit their use.
38.
39. ––
Portal Hypertension
Portal vein is formed by the union of superior mesenteric and splenic
veins. .
Normal pressure in the portal vein is 7–10 mm Hg.
Portal hypertension is present when the sustained elevation of portal
pressure is > 10 mm of Hg.
Portal hypertension is defined as an increase in the hepatic venous
pressure gradient to > 5 mm Hg.
It is caused by increased resistance to hepatic blood flow due to
cirrhosis and regenerative nodules, and increased splanchnic blood
flow due to splanchnic vasodilatation.
40. Causes of portal hypertension are:
Prehepatic causes: splenic AV fistula, splenic or portal vein
thrombosis, massive splenomegaly.
Presinusoidal intrahepatic causes: Sarcoidosis, schistosomiasis,
nodular regenerative hyperplasia, congenital hepatic fibrosis,
idiopathic portal fibrosis, early primary biliary cirrhosis, chronic
active hepatitis, myeloproliferative disorders, graft vs host disease.
41. Sinusoidal intrahepatic causes: Established cirrhosis, alcoholic hepatitis.
Postsinusoidal intrahepatic causes: Alcoholic terminal hyaline sclerosis,
veno- occlusive disease.
Postsinusoidal posthepatic causes: Budd-Chiari syndrome, membranous
IVC web, right heart failure, constrictive pericarditis.
Patients may present with any of the complications of portal
hypertension namely
1.Collateral circulation and varices
2.Ascites
3.Congestive splenomegaly, hypersplenism
42. Patients may present with any of the complications
of portal hypertension namely:
1.Collateral circulation and varices
2.Ascites
3.Congestive splenomegaly, hypersplenism
43. Site of Porto-
systemic anastomosis
Portal component Systemic
component
Clinical effect
Lower esophagus Esophageal
branches of left
gastric vein
Azygous veins Submucosal
gastroesophageal
varices
Upper anal canal superior rectal vein Middle inferior
rectal veins
May be confused
with hemorrhoids
Umbilical (anterior
abdominal wall)
Veins of
ligamentum teres
Superior /inferior
epigastric veins
Caput medusae
Bare area of liver Hepatic /portal
veins
Inferiorphrenic
veins
44. The primary treatment of portal hypertension is treatment of the cause,
or removal of offending agents, if possible.
.
Other measures include measures to lower portal venous pressure and
treatment of complications.
Non-selective b-blockers (such as propranolol) to reduce portal venous
pressure. Nonselective β-adrenergic blockers reduce portal pressure by
two mechanisms: decrease in cardiac output (β1)
splanchnic vasoconstriction (β2).
Low salt diet.
Diuretics for ascites: Spironolactone to counteract sodium retention;
loop diuretics can also be added.
45. Vasoactive drugs—reduce hepatic venous pressure gradient (in variceal
bleeding): Somatostatin or its analogues octreotide and vapreotide,
vasopressin or terlipressin-splanchnic vasoconstrictors but have ischemic
side-effects.
Portosystemic shunt procedures:––
TIPS (transjugular intrahepatic portosystemic shunt) An intrahepatic
shunt is created between portal and hepatic veins. This may lead to
higher risk of hepatic encephalopathy. Frequently stenosis occurs
necessitating repeat procedure.
Surgically created portosystemic shunts: These are major procedures,
not done routinely now, may be undertaken when TIPS is not
possible.
46. •Varices
Cirrhosis increases portal pressure as a result of chronic inflammation.
Fibrosis and regenerative nodules cause resistance to splanchnic flow
and lead to formation of portosystemic collaterals.
Progression of portal hypertension leads to increased local production
of nitric oxide and exacerbates splanchnic vasodilation.
Rupture of the high-pressure collaterals that are formed is a highly
lethal and feared complication of portal hypertension.
48. Medications to Management of acute variceal bleeding consists of:
1.General resuscitation (fluid resuscitation and replacement blood and
blood products, hemodynamic and respiratory support).
Aggressive intravascular volume replacement can lead to resistant or
recurrent
bleeding because bleeding is a pressure-related phenomenon. Elective
intubation of the trachea for airway protection is often warranted
2.Specific measures to control the bleeding.
49. 2.Measures to prevent hepatic encephalopathy.
2.The specific measures
to control bleeding are:
1.Pharmacological measures which cause vasoconstriction to stop
bleeding.
2.The drugs used are vasopressin (20 units in 200 mL over 20 min
(check dose) with ECG monitoring, terlipressin, glypressin,
somatostatin and octreotide (50–100 mcg/h as an infusion).
50. 2.Mechanical measures inflatable balloons for tamponadeby direct
3. pressure. These are Sengstaken-Blakemore tube (esophageal and
4. gastric balloon),
Minnesota tube (modification of Sengstaken-Blakemore tube) and
Linton-Nachlas tube with a single large gastric balloon.
3.Surgical measures: Endoscopic variceal ligation.
51. Ascites
Ascites is the most common complication
of cirrhosis leading to hospitalization.
52. Nonhepatic causes account for 15% of ascites and include malignancy,
cardiac failure, renal disease, pancreatitis, and tuberculosis.
Paracentesis is an important aid in diagnosis.
A serum-ascites albumin gradient greater than 1.1 mg/dL indicates
portal hypertension with 97% accuracy..
Once ascites becomes refractory to maximum standard medical
therapy, therapeutic options are limited and include serial
paracentesis, liver transplantation, TIPS placement, and
peritoneovenous shunt.
53. Risk factors for development of spontaneous bacterial peritonitis
include a prior episode of this acute infection, gastrointestinal
bleeding, and an ascites albumin level of less than 1.5 g/dL.
Long-term antibiotic prophylaxis with norfloxacin or
trimethoprim/sulfamethoxizole is recommended for patients who have
survived an episode of spontaneous bacterial peritonitis
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70. Clinical Implications Of Impaired Liver Function On The
Metabolism, Pharmacokinetics And Pharmacodynamics Of
Anesthetic Drugs :
Intravenous (IV) anesthetic agents:
Thiopentone:
Duration of action - prolonged due to - reduction in plasma proteins -
increase in unbound fraction of drug so dose may need to be reduced
Propofol:
Sensitivity to the sedative and cardiorespiratory depressant effects is
increased;
71. Etomidate:
May be used safely but offers little advantage over thiopentone.
Ketamine:
Has little effect on hepatic blood flow.
72. MUSCLE RELAXANTS
Succinyl choline:
•Reduced pseudocholinesterase concentrations.
•So Metabolism of succinylcholine may be delayed but is not practically
significant.
NMB’s:
•Increased volume of distribution and altered protein binding.
•May lead to an apparent resistance to nondepolarizing neuromuscular
blockers (NMBs).
73. Vecuronium:
Undergoes hepatic metabolism and may have a prolonged elimination
phase.
Atracurium and cisatracurium :
These are safer agents in liver disease.
Hoffmans degradation and non specific ester hydrolysis.
•
74. OPIOIDS
Morphine:
•Elimination of morphine - delayed - in cirrhotic patients
•Due to both reduced hepatic blood flow and extraction ratio.
•Accumulation of the active metabolite morphine- 6 glucuronide - In
patients with associated renal failure.
•May precipitate hepatic encephalopathy- in patients with
decompensated liver failure so it is best avoided
Fentanyl:
Given in low doses-it does not have an active metabolite and is renally
excreted.
•
.
75. •
Alfentanil:
•Elimination - reduced ,
•Volume of distribution - increased, and
• Protein binding - reduced by the lack of alpha-1-acid glycoprotein.
Remifentanil :
•Is ideally suited to intraoperative use
•It is metabolized by tissue and red cell esterases, which unlike plasma
esterases are preserved in patients with severe liver disease.
76. •All volatile anesthetics reduce cardiac output and mean arterial
pressure and thereby reduce liver blood flow.
•Isoflurane, sevoflurane,and desflurane undergo minimal hepatic
metabolism and can be regarded as safe.
•Desflurane is least metabolized and provides the quickest emergence
from anesthesia.
•It also relatively preserves hepatic blood flow (it has minimal effects
on the hepatic arterial buffer response) and cardiac output.
77. Drugs Drugs safe in liver
disease
Drugs to be used with
caution,needs
dose reduction
Contra
indicated
PREMEDICATI
ON
Lorazepam Midazolam,Diazepam
INDUCTION Propofol,Thiopentone
sodium,Etomidate
VOLATILE
AGENTS
Desflurane,Sevoflurane
,
Isoflurane,N2O
Enflurne Halothane
MUSCLE
RELAXANTS
Atracurium,Cisatracuri
um
Rocuronium,Vecuroni
um,
Succinyl choline
Pancuroniu
m
OPIOIDS Remifentanyl Fentanyl,Alfentanyl Morphine,
Pethidine
LOCAL
ANESTHETICS
- Lignocaine,Bupivacai
n
e
ANALGESICS Paracetamol Nsaids
78. HALOTHANE HEPATITIS
Halothane hepatitis is hepatotoxicity associated with halothane
administration within 3 weeks .
•Two types of hepatotoxicity are seen with halothane.
79. Type I
•common, benign and self limiting and occurs due to
• reductive biotransformation of halothane.
•A transient mild increase in serum transaminase and
glutathione S- transferase concentrations is seen.
•Type I hepatotoxicity is not characterized by jaundice or
• clinically evident hepatocellular disease.
80. Halothane hepatitis (type II hepatotoxicity) is probably
immune mediated.
•Oxidative metabolism of halothane leads to formation of
trifluroacetyl metabolites, which bind to liver proteins.
•In genetically susceptible individuals, antibodies are
• generated against these complexes and hepatotoxicity
• results.
•This is characterized fever, jaundice, very high serum
transaminase levels and pathologically by massive
centrilobular liver necrosis leading to fulminant liver
failure; with a high (50%) mortality rate
81. •Recent previous exposure
•Previous adverse reaction.
•Obesity,female,pregnancy.
•Drug allergy,recent viral hepatitis
•. Family history of halothane
• hepatotoxicity
82. Avoid halothane if:
•Previous exposure within 3 months.
•Previous adverse reaction to halothane.
•Pre existing liver disease.
•Family history of adverse reaction to halothane.
•Adverse reaction to other halogenated
hydrocarbon anesthetic.
83. Effect Of Hyperbilirubinemia On Coagulation Cascade
•Enteric absorption of fat-soluble vitamins, such as vitamin K, depends
on the presence of bile in the gut and an intact enterohepatic
circulation.
•Due to reduced drainage of bile,the sysnthesis of vitamin K dependent
clotting factors(factors II, VII, IX, and X) is reduced, resulting in
coagulopathy with elevated prothrombin and activated partial
thromboplastin times.
84. • Coagulopathy related to deficiency of Vit K dependent factors can
develop even after brief periods of disrupted biliary flow.
•Prolonged biliary obstruction can also cause liver injury(adding hepatic
component) with subsequent deterioration in the hepatic synthesis of
proteins, including coagulation factors.
•Usually, the coagulation disorders are moderate, and parenteral vitamin
K corrects the problem.
•Thrombocytopaenia and platelet dysfunction are also common.
85. ANESTHETIC MANAGEMENT
Pre Operative Optimisation
•Significant coagulopathy and anaemia in this patient needs attention.
•Prothrombin time, albumin estimation along with platelet count is to be
obtained.
•Vitamin K 10 mg. intra muscular or intra venous for 3 days,may correct a
prolonged PT.
•In patients with synthetic failure,this may not be adequate and platelet and
fresh frozen plasma transfusions may help.
•Fresh frozen plasma may be required if the PT is 1.5 times the control.
86. •platelets should be administered if the platelet count is <50,000/mm3.
•Cryoprecipitate is usually only indicated if the fibrinogen concentrations
are
1.0 g /litre.
•Psychological counselling and informed consent must be undertaken
along with other preparations.
•The patient is kept nil oral for 6-8 hours and supplemented with
intravenous fluids.
•Pre operatively oral tramadol used for pain abdomen.
87. •Nasogastric decompression with Ryle’s tube is mandatory due to the
pathology and the major laparotomy with anticipated delay in bowel
motility post operatively.
•H2 - receptor blocker, metoclopramide, as well as sodium citrate can
be administered pre operatively.
•Urinary bladder catheterisation - for proper assessment of input and
output of fluids.
88. •Preoperatively, gut sterilizers (lactulose, 30mL orally every 6 hours for 3
days before surgery with the last dose given within 12 hours of surgery
to reduce the endotoxin production from gut bacteria) and
•Frusemide/mannitol may be advised along with fluid administration
for a target urine output of more than 0.5 ml/kg/hr
•If patient is a chronic alcoholic, risk for neurologic deterioration is
present and hence thiamine, folate, and vitamin B12 supplements are
supplemented along with glucose.
89. Anesthetic goals
•Maintain hepatic blood flow,
•Avoid sympathetic stimulation,
•hypotension,
•hypoxia and hypocapnoea
•pressure effects and hepatic venous congestion and
• Avoid hepato toxic drugs
90. Premedication :
A short-acting benzodiazepine such as midazolam combined with
remifentanil.
The choice of anesthetic technique :
General anesthesia with endotracheal intubation and controlled
ventilation.
If the PT,INR and platelet count are in the acceptable range
epidural analgesia is supplemented to general anesthesia.
91. Choice of anesthetic agents:
•Opiod:
Fentanyl - in moderate doses.
•IV induction agent:
thiopentone,propofol or etomidate with titrated
doses.
•Muscle relaxant:
92. •Depolarizing:
Succinyl choline – safe
slightly prolonged duration is expected if the pseudo choline
esterase levels are low.
•Non depolarisers:
atracurium and cisatracurium - organ independent elimination.
Hoffmans degradation and non specific ester hydrolysis.
•inhalational agents :
isoflurane,sevoflurane and desflurane are safe in the concentrations
upto 1% used for maintainance.
93. •Reversal agents:
•There is risk of prolonged effects of anti cholinesterases (neostigmine)
but the
duration of anticholinergics is simultaneously prolonged and hence
there is no risk of residual curarisation.
•Suggamadex – agent of choice.(independant of liver for metabolism
and not protein bound)
94.
95. Intraoperative monitoring
•Non invasive monitoring consists of
Non invasive blood pressure, Pulse
oximetry,
ECG,
Temperature
End tidal carbon dioxide (EtCO2)
96. •Urine output has to be monitored for maintaining fluid balance.
•Central venous monitoring (CVP) is used as necessary during the intra
operative period.
•Further invasive monitoring is applied as indicated by surgical and
patient status.
98. Management Of Fluid And Blood In This Patient
•Large-bore i.v. access is mandatory
Crystalloids:
normally used initially
based on haemodynamics and the surgical loss of fluid and
blood
Colloids and blood products – FFP and Platelets
may be used as indicated and based on central filling
pressures and electrolytes
99. Post Operative Management
Post operative monitoring is required in Post Anaesthesia Care Unit or
HDU
•Epidural analgesia and Paravertebral and intercoastal blocks if INR<1.5
and platelet count > 1 lakh/mm3 can provide effective analgesia.
•Use of TAP blocks or local infiltration is recommended.
•IV patient-controlled analgesia using fentanyl is well tolerated in patients
with compensated liver disease.
•NSAIDs - avoided due to risk of gastrointestinal hemorrhage, platelet
dysfunction, and nephrotoxicity.
•Paracetamol - used with care and liver function monitored carefully. IM
or s.c injections risk formation of hematoma
